Miller John B, Aucott John N
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD.
J Clin Rheumatol. 2021 Dec 1;27(8):e540-e546. doi: 10.1097/RHU.0000000000001513.
BACKGROUND/HISTORICAL PERSPECTIVE: Lyme arthritis was described in 1977, after an apparent outbreak of juvenile idiopathic arthritis in Lyme, Connecticut. The evolution of the disease has been meticulously described with presentation dependent on disease duration and previous therapy.
Erythema migrans is typically the first manifestation. Untreated patients often develop early disseminated disease, characterized by migratory polyarthralgia, potentially with cardiac and/or neurologic sequelae. If untreated, most patients develop late Lyme arthritis, characterized as a monoarthritis or oligoarthritis, typically involving the knees. Serologies are strongly positive at this stage; if positive, Lyme PCR from synovial fluid confirms the diagnosis. Doxycycline is recommended for late Lyme arthritis, although amoxicillin or ceftriaxone may be considered.Initial antibiotic therapy for late Lyme arthritis is insufficient for a subset of patients. However, serologies and synovial fluid PCR are not useful at determining whether infection persists after oral therapy. As such, ceftriaxone is recommended in patients with inadequate response to doxycycline or amoxicillin.Approximately 10% of patients have persistent arthritis despite antimicrobial therapy, termed postinfectious Lyme arthritis, which is thought to be related to prolonged inflammation and unique microbial and host interaction. Therapy at this stage relies on immunosuppression and/or synovectomy.
Lyme arthritis provides unique insights into the complex interplay between microbes and host immunity. The progression from localized erythema migrans to early disseminated disease and late Lyme arthritis allows insight into arthritis initiation, and the study of postinfectious Lyme arthritis allows further insight into mechanisms of arthritis persistence.
背景/历史视角:莱姆关节炎于1977年被描述,此前在康涅狄格州莱姆出现了明显的青少年特发性关节炎疫情。该病的演变已被详细描述,其表现取决于疾病持续时间和先前的治疗情况。
游走性红斑通常是首发表现。未经治疗的患者常发展为早期播散性疾病,其特征为游走性多关节痛,可能伴有心脏和/或神经后遗症。若未经治疗,大多数患者会发展为晚期莱姆关节炎,其特征为单关节炎或寡关节炎,通常累及膝关节。在此阶段血清学检查呈强阳性;若为阳性,滑膜液的莱姆PCR可确诊。对于晚期莱姆关节炎,推荐使用多西环素,不过也可考虑阿莫西林或头孢曲松。晚期莱姆关节炎的初始抗生素治疗对一部分患者并不充分。然而,血清学检查和滑膜液PCR在确定口服治疗后感染是否持续方面并无帮助。因此,对于对多西环素或阿莫西林反应不佳的患者,推荐使用头孢曲松。尽管进行了抗菌治疗,仍有约10%的患者患有持续性关节炎,称为感染后莱姆关节炎,被认为与炎症持续时间延长以及独特的微生物与宿主相互作用有关。此阶段的治疗依赖免疫抑制和/或滑膜切除术。
莱姆关节炎为微生物与宿主免疫之间的复杂相互作用提供了独特见解。从局限性游走性红斑发展到早期播散性疾病以及晚期莱姆关节炎,有助于深入了解关节炎的发病机制,而对感染后莱姆关节炎的研究则有助于进一步深入了解关节炎持续存在的机制。